- Home
- / RenalytixAI
RenalytixAI
Stock Price
£0.1
2024-10-29
Market Capitalization
£15.2 M
2024-10-29
Revenue
$2.3 M
FY, 2024
RenalytixAI Summary
Company Summary
- Overview
- RenalytixAI is a company developing artificial intelligence (AI) that enables clinical diagnostic solutions for kidney disease. Its solution makes improvements in kidney disease diagnosis and prognosis, clinical care, and patient stratification for drug clinical trials.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- New York, NY, US | view all locations
- Website
- https://renalytix.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Steven Coca, Co-Founder
Fergus Fleming, CTO
Christopher Mills, Non-Executive Director
LocationsView all
5 locations detected
New York, NY HQ
United States
1460 Broadway
New York, NY
United States
101 6th Ave #324
London, England
United Kingdom
4 Lombard St
London, England
United Kingdom
Finsgate, 5-7 Cranwood St
Penarth, Wales
United Kingdom
Avon House, 19 Stanwell Rd
RenalytixAI Financials
Summary Financials
- Revenue (Q1, 2025)
- $522.0K
- Gross profit (Q1, 2025)
- $100.0K
- Net income (Q1, 2025)
- ($4.7M)
- Cash (Q1, 2025)
- $909.0K
- EBIT (Q1, 2025)
- ($4.1M)
- Enterprise value
- $18.4M
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026